The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. In this proof-of-concept study, we have measured the circulating levels of CGRP in 7 patients with high-frequency episodic migraine receiving the anti-CGRP receptor mAb erenumab for at least 6 months, to test the hypothesis that long-term blockade of CGRP receptors induces an increase in systemic CGRP levels via a classical up-regulation mechanism. Plasma CGRP levels were measured by a validated radioimmunoassay at baseline, and after 1 and 6 months of treatment with erenumab, 70 mg given sc every 4 weeks. We found (data expressed as the means ± SD): 38.34 ± 30.74 pg CGRP/ml of plasma at baseline, 38.19 ± 29.23 pg/ml after 1 month and 53.89 ± 28.03 pg/ml after 6 months of treatment. Thus, the average increase in plasma CGRP levels after 6 months of treatment was about + 40% compared to both baseline and 1-month treatments; such difference was not statistically significant because of high SD values in all groups. These preliminary findings need to be confirmed in larger, sufficiently powered experiments.

Tringali, G., Vollono, C., Calabresi, P., Navarra, P., A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB, <<THE JOURNAL OF HEADACHE AND PAIN>>, 2020; 21 (1): N/A-N/A. [doi:10.1186/s10194-020-01193-4] [http://hdl.handle.net/10807/165988]

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB

Tringali, Giuseppe;Vollono, Catello;Calabresi, Paolo;Navarra, Pierluigi
2020

Abstract

The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. In this proof-of-concept study, we have measured the circulating levels of CGRP in 7 patients with high-frequency episodic migraine receiving the anti-CGRP receptor mAb erenumab for at least 6 months, to test the hypothesis that long-term blockade of CGRP receptors induces an increase in systemic CGRP levels via a classical up-regulation mechanism. Plasma CGRP levels were measured by a validated radioimmunoassay at baseline, and after 1 and 6 months of treatment with erenumab, 70 mg given sc every 4 weeks. We found (data expressed as the means ± SD): 38.34 ± 30.74 pg CGRP/ml of plasma at baseline, 38.19 ± 29.23 pg/ml after 1 month and 53.89 ± 28.03 pg/ml after 6 months of treatment. Thus, the average increase in plasma CGRP levels after 6 months of treatment was about + 40% compared to both baseline and 1-month treatments; such difference was not statistically significant because of high SD values in all groups. These preliminary findings need to be confirmed in larger, sufficiently powered experiments.
2020
Inglese
Tringali, G., Vollono, C., Calabresi, P., Navarra, P., A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB, <<THE JOURNAL OF HEADACHE AND PAIN>>, 2020; 21 (1): N/A-N/A. [doi:10.1186/s10194-020-01193-4] [http://hdl.handle.net/10807/165988]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/165988
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact